Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 21 of 458 for:    DICLOFENAC

Diclofenac Potassium Alone Versus Diclofenac Potassium With Hyoscine-N-butyl Bromide (HBB in Endoscopy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04125771
Recruitment Status : Not yet recruiting
First Posted : October 14, 2019
Last Update Posted : October 14, 2019
Sponsor:
Collaborator:
Cairo University
Information provided by (Responsible Party):
Mahmoud Alalfy, Aljazeera Hospital

Brief Summary:
Diclofenac is a proven, commonly prescribed nonsteroidal anti-inflammatory drug (NSAID) that has analgesic, anti-inflammatory, and antipyretic properties, and has been shown to be effective in treating a variety of acute and chronic pain and inflammatory conditions.

Condition or disease Intervention/treatment Phase
Pain Diagnostic Test: Diclofenac + HBB with hysteroscopy Diagnostic Test: Diclofenav + placebo Not Applicable

Detailed Description:

Diclofenac is a proven, commonly prescribed nonsteroidal anti-inflammatory drug (NSAID) that has analgesic, anti-inflammatory, and antipyretic properties, and has been shown to be effective in treating a variety of acute and chronic pain and inflammatory conditions.

. As with all NSAIDs, diclofenac exerts its action via inhibition of prostaglandin synthesis by inhibiting cyclooxygenase-1 (COX-1)


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Diagnostic
Official Title: Diclofenac Potassium Alone Versus Diclofenac Potassium With Hyoscine-N-butyl Bromide (HBB in Endoscopy
Estimated Study Start Date : October 16, 2019
Estimated Primary Completion Date : March 25, 2020
Estimated Study Completion Date : April 1, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Endoscopy Potassium

Arm Intervention/treatment
Diclofenac + HBB
Women who will receive Diclofenac + HBB
Diagnostic Test: Diclofenac + HBB with hysteroscopy
Giving Diclofenac + HBB with hysteroscopy

Diagnostic Test: Diclofenav + placebo
Giving Diclofenac + placebo with hysteroscopy

Diclofenav + placebo
Women who will receive Diclofenav + placebo
Diagnostic Test: Diclofenac + HBB with hysteroscopy
Giving Diclofenac + HBB with hysteroscopy

Diagnostic Test: Diclofenav + placebo
Giving Diclofenac + placebo with hysteroscopy




Primary Outcome Measures :
  1. The number of women who will not feel pain [ Time Frame: within half an hour ]
    the effect of medications on pain sensation



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   female who will undergo hysteroscopy
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • 1. Patients indicated for diagnostic hysteroscopy including infertility, bleeding, suspected intrauterine pathologies (eg polypi , septea) 2. Reproductive age 20 - 40yrs

Exclusion Criteria:

  • 1. Menopausal and amenorrhic patients 2. Contraindication to office hysteroscopy such as:- pelvic inflammatory disease, marked cervical stenosis, pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04125771


Contacts
Layout table for location contacts
Contact: Mahmoud Alalfy, PhD 01002611058 mahmoudalalfy@ymail.com
Contact: Ahmed Rashwan, MD 010o2611058 mahmoudalalfy@ymail.com

Locations
Layout table for location information
Egypt
Algazeerah and Kasralainy hospital
Giza, Egypt
Sponsors and Collaborators
Aljazeera Hospital
Cairo University

Layout table for additonal information
Responsible Party: Mahmoud Alalfy, Researcher , lecturer ,Obstetrics and Gynecology , National Research Centre, Aljazeera Hospital
ClinicalTrials.gov Identifier: NCT04125771     History of Changes
Other Study ID Numbers: Diclofenac potassium
First Posted: October 14, 2019    Key Record Dates
Last Update Posted: October 14, 2019
Last Verified: October 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Diclofenac
Scopolamine
Bromides
Butylscopolammonium Bromide
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anticonvulsants
Adjuvants, Anesthesia
Antiemetics
Autonomic Agents
Gastrointestinal Agents
Mydriatics
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Muscarinic Antagonists
Parasympatholytics